HRP20140671T1 - Derivati tioksantena za lijeäśenje infektivnih bolesti - Google Patents
Derivati tioksantena za lijeäśenje infektivnih bolesti Download PDFInfo
- Publication number
- HRP20140671T1 HRP20140671T1 HRP20140671AT HRP20140671T HRP20140671T1 HR P20140671 T1 HRP20140671 T1 HR P20140671T1 HR P20140671A T HRP20140671A T HR P20140671AT HR P20140671 T HRP20140671 T HR P20140671T HR P20140671 T1 HRP20140671 T1 HR P20140671T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- amino
- mono
- substance according
- group
- Prior art date
Links
- 208000035473 Communicable disease Diseases 0.000 title claims 5
- 238000011282 treatment Methods 0.000 title claims 5
- 229940054058 antipsychotic thioxanthene derivative Drugs 0.000 title 1
- 150000005075 thioxanthenes Chemical class 0.000 title 1
- 239000000126 substance Substances 0.000 claims 14
- -1 hydroxy, amino Chemical group 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 4
- 150000001721 carbon Chemical group 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
- 125000004845 (C1-C6) alkylsulfonylamino group Chemical group 0.000 claims 2
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 2
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 2
- 125000005947 C1-C6 alkylsulfonyloxy group Chemical group 0.000 claims 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003320 C2-C6 alkenyloxy group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
- 125000001769 aryl amino group Chemical group 0.000 claims 2
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 2
- 125000004657 aryl sulfonyl amino group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000005241 heteroarylamino group Chemical group 0.000 claims 2
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims 2
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 2
- 125000005226 heteroaryloxycarbonyl group Chemical group 0.000 claims 2
- 125000005419 heteroarylsulfonylamino group Chemical group 0.000 claims 2
- 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims 2
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims 2
- 229910052740 iodine Inorganic materials 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 235000013877 carbamide Nutrition 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012678 infectious agent Substances 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/10—Dibenzothiopyrans; Hydrogenated dibenzothiopyrans
- C07D335/12—Thioxanthenes
- C07D335/20—Thioxanthenes with hydrocarbon radicals, substituted by amino radicals, directly attached in position 9
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (14)
1. Tvar opće formule (I)
[image]
pri čemu
V je odabran iz grupe koja se sastoji od S, SO2, SO, O i NH;
W je C=CH-(CHX)n-CX(Rg)(R10) ili je W C=CH-(CHX)n-1-CH=(Rg)(R10);
n je cijeli broj u rasponu od 1 do 5;
svaki X je zasebno odabran iz grupe koja se sastoji od vodika, halogena, hidroksi, amino, nitro, C1-6-alkil i C1-6-alkoksi;
R1, R3, R4, R5, R6, R7 i R8 su svaki zasebno odabrani iz grupe koja se sastoji od vodika, halogena, hidroksi, amino, nitro, C1-6-alkil, C2-6-alkenil, C2-6-alkinil i C1-6-alkoksi, C2-6-alkeniloksi, karboksi, i C1-6-alkoksikarbonil, i C1-6-alkilkarbonil, formil, i C1-6-alkilsulfonilamino, aril, ariloksikarbonil, ariloksi, arilkarbonil, arilamino, arilsulfonilamino, heteroaril, heteroariloksikarbonil, heteroariloksi, heteroarilkarbonil, heteroarilamino, heteroarilsulfonilamino, heterociklil, heterocikloksikarbonil, heterocikliloksi, heterociklilkarbonil, heterociklilamino, heterociklilsulfonilamino, mono- i di(C1-6-alkil)amino, karbamoil, mono- i di(C1-6-alkil)aminokarbonil, amino- C1-6-alkil-aminokarbonil, mono- i di(C1-6-alkil)amino- C1-6-alkil-aminokarbonil, C1-6-alkilkarbonilamnio, amino- C1-6-alkil-karbonilamino, mono- i di(C1-6-alkil)amino- C1-6-alkil-karbonilamino, amino- C1-6-alkil-amino, mono- i di(C1-6-alkil)amino- C1-6-alkil-amino, cijano, gvanidino, karbamido, C1-6-alkanoiloksi, C1-6-alkilsulfonil, C1-6-alkilsulfinil, C1-6-alkilsulfoniloksi, aminosulfonil, mono- i di(C1-6-alkil)aminosulfonil i C1-6-alkiltio;
R2 je odabran iz grupe koja se sastoji od F, Cl, Br, I, CH2Y, CHY2 i CY3, gdje je Y atom halogena; i R9 i R10 zajedno s atomom ugljika za koji su povezani tvore C3-6-cikloalkil ili C3-6-heterociklil, poželjno heterociklil koji sadrži dušik;
kao i njihove soli.
2. Tvar u skladu s patentnim zahtjevom 1 pri čemu je V S.
3. Tvar u skladu s bilo kojim od patentnih zahtjeva 1 ili 2, pri čemu je n 2, 3 ili 4.
4. Tvar u skladu s bilo kojim od patentnih zahtjeva 1-3, pri čemu R9 i R10 zajedno s atomom ugljika za kojeg su vezani tvore piperidinil ili piperazinil, poželjno piperidinil.
5. Tvar u skladu s bilo kojim od patentnih zahtjeva 1-4, pri čemu R9 i R10 zajedno s atomom ugljika za kojeg su vezani tvore heteroaril ili heterociklil koji sadrži dušik gdje je atom dušika odvojen dvjema atomima ugljika od atoma ugljika za koji su R9 i R10 vezani.
6. Tvar opće formule
[image]
pri čemu
V je odabran iz grupe koja se sastoji od S, SO2, SO, O i NH;
W' je C=CH;
n je cijeli broj u rasponu od 1 do 6;
svaki X je zasebno odabran iz grupe koja se sastoji od vodika, halogena, hidroksi, amino, nitro, C1-6-alkil i C1-6-alkoksi;
Z je odabran između C, N, S ili O;
R1, R3, R4, R5, R6, R7, R8 R11, R12, R14 i R15 su svaki zasebno odabrani iz grupe koja se sastoji od vodika, halogena, hidroksi, amino, nitro, C1-6-alkil, C2-6-alkenil, C2-6-alkinil i C1-6-alkoksi, C2-6-alkeniloksi, karboksi, i C1-6-alkoksikarbonil, i C1-6-alkilkarbonil, formil, i C1-6-alkilsulfonilamino, aril, ariloksikarbonil, ariloksi, arilkarbonil, arilamino, arilsulfonilamino, heteroaril, heteroariloksikarbonil, heteroariloksi, heteroarilkarbonil, heteroarilamino, heteroarilsulfonilamino, heterociklil, heterocikloksikarbonil, heterocikliloksi, heterociklilkarbonil, heterociklilamino, heterociklilsulfonilamino, mono- i di(C1-6-alkil)amino, karbamoil, mono- i di(C1-6-alkil)aminokarbonil, amino- C1-6-alkil-aminokarbonil, mono- i di(C1-6-alkil)amino- C1-6-alkil-aminokarbonil, C1-6-alkilkarbonilamnio, amino- C1-6-alkil-karbonilamino, mono- i di(C1-6-alkil)amino- C1-6-alkil-karbonilamino, amino- C1-6-alkil-amino, mono- i di(C1-6-alkil)amino- C1-6-alkil-amino, cijano, gvanidino, karbamido, C1-6-alkanoiloksi, C1-6-alkilsulfonil, C1-6-alkilsulfinil, C1-6-alkilsulfoniloksi, aminosulfonil, mono- i di(C1-6-alkil)aminosulfonil i C1-6-alkiltio; i
R2 je odabran iz grupe koja se sastoji od F, Cl, Br, I, CH2Y, CHY2 i CY3, gdje je Y atom halogena; i
R13 je vodik, halogen, hidroksi, amino, nitro, C1-6-alkil ili C1-6-alkoksi;
ili njihove soli.
7. Tvar u skladu s bilo kojim od patentnih zahtjeva 1-6 za uporabu u tretmanu liječenja.
8. Tvar u skladu s bilo kojim od patentnih zahtjeva 1-7 za uporabu u liječenju infektivne bolesti.
9. Tvar u skladu s bilo kojim od patentnih zahtjeva 1-8 za uporabu u liječenju infektivne bolesti u kombinaciji s dodatnim antiinfektivnim agensom.
10. Tvar u skladu s bilo kojim od patentnih zahtjeva 1-9 gdje je infektivna bolest uzrokovana infektivnim agensom otpornim na lijekove.
11. Uporaba tvari definirane u bilo kojem od prethodnih patentnih zahtjeva 1-10 za proizvodnju lijeka za liječenje ili profilaksu infektivne bolesti.
12. Uporaba u skladu s patentnim zahtjevom 11, pri čemu je navedena tvar korištena ili dana u klinički značajnoj količini.
13. Farmaceutski sastav sadrži tvar u skladu s bilo kojim od patentnih zahtjeva 1-6 i najmanje jedan farmaceutski prihvatljivi nosač ili ekscipijens.
14. Farmaceutski sastav u skladu s patentnim zahtjevom 13, sadrži klinički značajnu količinu tvari u skladu s bilo kojim od patentnih zahtjeva 1-6.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20291809P | 2009-04-20 | 2009-04-20 | |
| EP09158229A EP2246349A1 (en) | 2009-04-20 | 2009-04-20 | Treatment of infectious diseases |
| PCT/EP2010/055176 WO2010122012A1 (en) | 2009-04-20 | 2010-04-20 | Thioxanthene derivatives for the treatment of infectious diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140671T1 true HRP20140671T1 (hr) | 2014-10-10 |
Family
ID=40935562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140671AT HRP20140671T1 (hr) | 2009-04-20 | 2014-07-14 | Derivati tioksantena za lijeäśenje infektivnih bolesti |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8604059B2 (hr) |
| EP (3) | EP2246349A1 (hr) |
| JP (2) | JP5854987B2 (hr) |
| CN (1) | CN102459245B (hr) |
| AU (1) | AU2010240999B2 (hr) |
| CA (1) | CA2759364A1 (hr) |
| DK (1) | DK2421858T3 (hr) |
| EA (1) | EA022060B1 (hr) |
| ES (1) | ES2484016T3 (hr) |
| HK (1) | HK1170733A1 (hr) |
| HR (1) | HRP20140671T1 (hr) |
| MX (1) | MX2011011062A (hr) |
| NZ (1) | NZ596158A (hr) |
| PL (1) | PL2421858T3 (hr) |
| SI (1) | SI2421858T1 (hr) |
| WO (1) | WO2010122012A1 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009007235A (es) * | 2007-01-05 | 2009-10-16 | Bkg Pharma Aps | "derivados de tioxanteno utiles para el tratamiento de enfermedades infecciosas.". |
| EP2246349A1 (en) * | 2009-04-20 | 2010-11-03 | BKG Pharma ApS | Treatment of infectious diseases |
| RU2019101646A (ru) * | 2016-06-23 | 2020-07-23 | Биоимикс Аб | Противоинфекционные гетероциклические соединения и варианты их применения |
| RU2738405C1 (ru) * | 2020-05-26 | 2020-12-11 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермский государственный национальный исследовательский университет" | АМИД (Е)-2-АМИНО-4-ОКСО-5-(2-ОКСО-2-ФЕНИЛЭТИЛИДЕН)-1-(3-ЭТОКСИКАРБОНИЛ)-4,5,6-7-ТЕТРАГИДРОБЕНЗО[b]ТИОФЕН-2-ИЛ)4,5-ДИГИДРО-1Н-ПИРРОЛ-3-КАРБОНОВОЙ КИСЛОТЫ, ОБЛАДАЮЩИЙ ПРОТИВОМИКРОБНОЙ АКТИВНОСТЬЮ |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1033663B (de) * | 1954-09-18 | 1958-07-10 | Bayer Ag | Verfahren zur Herstellung von N-Alkyl-piperidylmethyl-phenthiazinen |
| DE1049865B (de) * | 1955-09-07 | 1959-02-03 | Farbenfabriken Bayer Aktiengesellschaft, Leverkusen-Bayerwerk | Verfahren zur Herstellung von in 3-Stellung acylierten Phenthiazinderivaten |
| LU39637A1 (hr) | 1960-01-13 | |||
| US3449334A (en) | 1967-10-26 | 1969-06-10 | Smithkline Corp | 9-(2-(2-piperidinyl)ethyl) and 9-(2-(2-pyrrolidinyl)ethyl)acridanes |
| AU625071B2 (en) | 1988-04-20 | 1992-07-02 | Merrell Dow Pharmaceuticals Inc. | N-alkylamino derivatives of aromatic, tricyclic compounds in the treatment of drug-resistant protozoal infections |
| JP3037988B2 (ja) | 1990-09-29 | 2000-05-08 | キーパー株式会社 | 合成樹脂製蛇腹製品の射出ブロー成形方法 |
| AU2002325192B2 (en) | 2001-07-06 | 2008-05-22 | Veloxis Pharmaceuticals, Inc. | Controlled agglomeration |
| DE10136060A1 (de) | 2001-07-25 | 2003-02-13 | Roche Diagnostics Gmbh | System zur Separation von magnetisch anziehbaren Partikeln |
| US7544681B2 (en) * | 2001-09-27 | 2009-06-09 | Ramot At Tel Aviv University Ltd. | Conjugated psychotropic drugs and uses thereof |
| AU2003294235A1 (en) * | 2002-10-22 | 2004-05-13 | The Trustees Of The University Of Pennsylvania | Fragments and activity of rel protein in m. tuberculosis adn other uses thereof |
| AU2003205543A1 (en) | 2003-01-14 | 2004-08-10 | Lifecycle Pharma A/S | Dry dispersions |
| ATE532517T1 (de) * | 2003-11-13 | 2011-11-15 | Noa Sic Aps | Thioridazin und seine derivate zur umkehr von antimikrobieller arzneimittelresistenz |
| CN1976723B (zh) * | 2004-04-30 | 2010-12-29 | Bkg制药有限公司 | 制备治疗或预防感染性疾病的药物的用途 |
| DE102006030835B3 (de) | 2006-07-04 | 2007-10-18 | Forschungszentrum Karlsruhe Gmbh | Hochporöses magnetisches temporäres Festbett |
| CA2662215A1 (en) * | 2006-09-01 | 2008-03-06 | Immune Control, Inc. | Novel compositions and methods for treatment of diseases related to activated lymphocytes |
| MX2009007235A (es) | 2007-01-05 | 2009-10-16 | Bkg Pharma Aps | "derivados de tioxanteno utiles para el tratamiento de enfermedades infecciosas.". |
| EP2246349A1 (en) * | 2009-04-20 | 2010-11-03 | BKG Pharma ApS | Treatment of infectious diseases |
-
2009
- 2009-04-20 EP EP09158229A patent/EP2246349A1/en not_active Withdrawn
-
2010
- 2010-04-20 AU AU2010240999A patent/AU2010240999B2/en not_active Ceased
- 2010-04-20 PL PL10713994T patent/PL2421858T3/pl unknown
- 2010-04-20 CN CN201080027053.2A patent/CN102459245B/zh not_active Expired - Fee Related
- 2010-04-20 US US13/265,149 patent/US8604059B2/en not_active Expired - Fee Related
- 2010-04-20 JP JP2012506464A patent/JP5854987B2/ja not_active Expired - Fee Related
- 2010-04-20 DK DK10713994.1T patent/DK2421858T3/da active
- 2010-04-20 EA EA201171269A patent/EA022060B1/ru not_active IP Right Cessation
- 2010-04-20 WO PCT/EP2010/055176 patent/WO2010122012A1/en active Application Filing
- 2010-04-20 ES ES10713994.1T patent/ES2484016T3/es active Active
- 2010-04-20 CA CA2759364A patent/CA2759364A1/en not_active Abandoned
- 2010-04-20 MX MX2011011062A patent/MX2011011062A/es active IP Right Grant
- 2010-04-20 EP EP10713994.1A patent/EP2421858B1/en not_active Not-in-force
- 2010-04-20 NZ NZ596158A patent/NZ596158A/xx not_active IP Right Cessation
- 2010-04-20 SI SI201030678T patent/SI2421858T1/sl unknown
- 2010-04-20 EP EP14166490.4A patent/EP2778166A1/en not_active Withdrawn
-
2012
- 2012-11-14 HK HK12111516.8A patent/HK1170733A1/xx not_active IP Right Cessation
-
2013
- 2013-11-04 US US14/071,260 patent/US20140066451A1/en not_active Abandoned
-
2014
- 2014-07-14 HR HRP20140671AT patent/HRP20140671T1/hr unknown
- 2014-07-25 JP JP2014152272A patent/JP2014240401A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN102459245A (zh) | 2012-05-16 |
| EA022060B1 (ru) | 2015-10-30 |
| MX2011011062A (es) | 2011-11-18 |
| NZ596158A (en) | 2013-02-22 |
| US20120122880A1 (en) | 2012-05-17 |
| EP2778166A1 (en) | 2014-09-17 |
| PL2421858T3 (pl) | 2014-10-31 |
| EP2421858A1 (en) | 2012-02-29 |
| AU2010240999B2 (en) | 2012-09-20 |
| JP2012524118A (ja) | 2012-10-11 |
| DK2421858T3 (en) | 2014-07-14 |
| JP2014240401A (ja) | 2014-12-25 |
| US8604059B2 (en) | 2013-12-10 |
| US20140066451A1 (en) | 2014-03-06 |
| WO2010122012A1 (en) | 2010-10-28 |
| JP5854987B2 (ja) | 2016-02-09 |
| CA2759364A1 (en) | 2010-10-28 |
| ES2484016T3 (es) | 2014-08-08 |
| SI2421858T1 (sl) | 2014-09-30 |
| EP2421858B1 (en) | 2014-04-30 |
| CN102459245B (zh) | 2015-01-28 |
| HK1170733A1 (en) | 2013-03-08 |
| EP2246349A1 (en) | 2010-11-03 |
| EA201171269A1 (ru) | 2012-03-30 |
| AU2010240999A1 (en) | 2011-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140671T1 (hr) | Derivati tioksantena za lijeäśenje infektivnih bolesti | |
| CY1120141T1 (el) | Παραγωγο βενζαμιδιου ως αναστολεας απακετυλασης ιστονης με ισχυρη διαφοροποιητικη και αντιπολλαπλασιαστικη δραστικοτητα | |
| MXPA06002296A (es) | Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos. | |
| RS107504A (en) | Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compostions including the same, and methods for their use | |
| TW200518758A (en) | HIV replication inhibiting purine derivatives | |
| BRPI0415759A (pt) | compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia | |
| CY1113323T1 (el) | Ενωσεις τετραϋδροφουρο[3,4-d]διοξολανιου για χρηση στη θεραπεια ιικων μολυνσεων και καρκινου | |
| GT200600496A (es) | Sales, profarmacos y formulaciones de 1-[5-(4-amino-7-isopropil-7h-pirrolo[2,3-d]piirimidin-5-carbonil)-2-metoxi-feil]-3-(2,4-dicloro-fenil)-urea. | |
| HRP20110607T1 (hr) | Derivati tioksantena kao samostalna intiinfektivna sredstva namijenjena upotrebi u liječenju zaraznih bolesti | |
| CY1107974T1 (el) | Παραγωγα κινολινης και κιναζολινης εχοντα συναφεια προς τους υποδοχεις τυπου 5ht1 | |
| WO2007029029A3 (en) | Tetracyclic indole derivatives as antiviral agents | |
| CY1110332T1 (el) | Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους | |
| ECSP034897A (es) | Nucleosidos 4'-sustituidos | |
| WO2006046039A3 (en) | Tetracyclic indole derivatives as antiviral agents | |
| ME00590A (en) | N-(aminoheteroaryl)-1h-indole-2-carboxamide derivatives, and preparation and therapeutic application thereof | |
| CY1112178T1 (el) | Παραγωγα πιπεραζινης και χρηση αυτων ως θεραπευτικων παραγοντων | |
| ATE397605T1 (de) | Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol | |
| BRPI0418102A (pt) | derivados de quinolina | |
| HRP20070505B1 (hr) | Spiro-oksindol spojevi i njihove upotrebe kao terapijska sredstva | |
| JP2011219498A5 (hr) | ||
| EA200602130A1 (ru) | Замещенные арилацилтиомочевины и родственные соединения; ингибиторы репликации вирусов | |
| CY1109880T1 (el) | ΑΝΤΑΓΩΝΙΣΤΗΣ CaSR | |
| CY1115058T1 (el) | Παραγωγα 1,2,3- τριαζολης για χρηση ως αναστολεις στεατοϋλο-coa δεσατουρασης | |
| MX2009012613A (es) | Tiazoles substituidos por heteroarilo y su uso como agentes antivirales. | |
| JP2017530983A5 (hr) |